QBiotics appoints Geoff Miller as Non-executive Director

BRISBANE, 11 June 2026

QBiotics Group Limited (QBiotics) is pleased to announce the appointment of Mr Geoff Miller to its Board as a Non-executive Director, effective 15 June 2026.

Geoff is an experienced chair and Non-executive Director with strong expertise in capital markets, corporate finance, governance and the commercialisation of growth-stage businesses, particularly in life sciences and financial services. He brings more than 30 years of board experience across listed companies in multiple international markets.

He has held chair and Non-executive Director roles across a broad range of listed and private companies, from micro-cap business to multi-billion dollar multinational organisations. He currently serves as Chairman of TSP Advanced Technologies plc (AQSE: TSP), a UK medical device company, and as a director of several private companies across the life sciences and financial services sectors.

Geoff has extensive experience in capital raising, M&A, IPO preparation and shareholder engagement, having led and supported companies through both public and private market transactions across sectors including life sciences, specialty finance, insurance and real estate.

Earlier in his career, Geoff co-founded a Guernsey-based venture capital business and held senior roles in equity research and investment management in the City of London.

QBiotics’ Chair, Simon Pollard said of the appointment, “On behalf of my fellow directors, I am delighted to welcome Geoff to the Board of QBiotics. His deep expertise in capital markets, corporate finance and governance will be highly valuable as we progress the implementation of our 2026–2027 strategic plan. Geoff’s experience in supporting growth-stage companies through capital formation and market development strengthens the Board’s capability in areas aligned to our strategic priorities, and will support QBiotics’ continued evolution as we advance our clinical and commercial objectives.”

Geoff Miller commented, “QBiotics has built a genuinely differentiated science platform. I am delighted to be joining the Board at this important stage of the Company’s development, and I look forward to working with Simon, and my fellow directors and management, to bring capital markets and governance discipline to bear as QBiotics advances its clinical programmes and prepares for its next phase of growth.”

— ends —
 

FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
NOTES FOR EDITORS

ABOUT QBIOTICS

QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.

QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. In a Phase II soft tissue sarcoma study the drug delivered an injected tumour Objective Response Rate (ORR) of 80%, with no serious Adverse Events, and translational research validating immunological responses. A Phase II study in head & neck cancer is soon to be reported and impressive safety and efficacy outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I/IIa safety study and efficacy reported for nine different tumour types.

QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human clinical Phase I/IIa study treating Venous Leg Ulcers.

Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of the drug secured for both programmes.

QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complemented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, and translational drug development.

QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.

For more, head to: QBiotics.com or LinkedIn